Trends Immunol. 2024 Dec 24:S1471-4906(24)00304-1. doi: 10.1016/j.it.2024.12.002. Online ahead of print.
ABSTRACT
Tumor-initiating cells (TICs) are particularly efficient at evading detection and elimination by the human immune system. Recent data from Yang and collaborators demonstrate that – at least in preclinical hepatocellular carcinoma models – the immunological privilege of CD49f+ TICs can be limited by targeting CD155, resulting in restored sensitivity to immune checkpoint inhibitors.
PMID:39721855 | DOI:10.1016/j.it.2024.12.002